ArticleWorld journal of urology2022
Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility.
Article in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Comparison of Perioperative and Oncologic Outcomes Between Robotic and Open Retroperitoneal Lymph Node Dissection in Testicular Cancer: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2026Pooled it
- External validation of the heidenreich criteria for patients with post-chemotherapy residual masses of non-seminomatous germ cell tumor.The Canadian journal of urology · 2026Article
- Research trends and collaboration patterns in robotic retroperitoneal lymph node dissection for testicular cancer.Journal of robotic surgery · 2026Article
- Single-cell and spatial transcriptome analysis reveals the potential therapeutic targets for testicular sex cord-stromal cell tumor.Biomarker research · 2026Article
- Laparoscopic Bilateral Nerve-Sparing Retroperitoneal Lymph Node Dissection for Testicular Cancer After Chemotherapy.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- [Retroperitoneal lymphadenectomy (RPLND) for the treatment of testicular germ cell tumors-open or robotic? Pro open surgery : RPLND in the management of testis cancer].Urologie (Heidelberg, Germany) · 2025Review
- Matched-pair analysis of peri-operative and oncological outcomes of robot-assisted vs open retroperitoneal lymph node dissection.BJU international · 2025Article
- Robotic Retroperitoneal Lymph Node Dissection for Testicular Cancer-First Experience and Learning Curve of a Single Surgeon.Cancers · 2025Article
- Article
- Article
- Lymph Node Dissection in Testicular Cancer: The State of the Art and Future Perspectives.Current oncology reports · 2024Review
- Re: Post-chemotherapy robot-assisted retroperitoneal lymph node dissection for metastatic germ cell tumors: safety and perioperative outcomes. World J Urol. 2023 Jul 28. doi: 10.1007/s00345-023-04536-3.World journal of urology · 2023Article
- Post-chemotherapy robot-assisted retroperitoneal lymph node dissection for metastatic germ cell tumors: safety and perioperative outcomes.World journal of urology · 2023Article
- Retroperitoneal lymph node dissection for testicular cancer is a demanding procedure: detailed real-life data of complications and additional surgical procedures in 295 cases.World journal of urology · 2023Article
- Comparison of laparoscopic, robotic, and open retroperitoneal lymph node dissection for non-seminomatous germ cell tumor: a single-center retrospective cohort study.World journal of urology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 17 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the perioperative safety, functional and immediate post-operative oncological outcomes of minimally invasive RPLND (miRPLND) for testis cancer.
methodsWe performed a retrospective multi-centre cohort study on testis cancer patients treated with miRPLND from 16 institutions in eight countries. We measured clinician-reported outcomes stratified by indication. We performed logistic regression to identify predictors for maintained postoperative ejaculatory function.
resultsData for 457 men undergoing miRPLND were studied. miRPLND comprised laparoscopic (n = 56) or robotic (n = 401) miRPLND. Indications included pre-chemotherapy in 305 and post-chemotherapy in 152 men. The median retroperitoneal mass size was 32 mm and operative time 270 min. Intraoperative complications occurred in 20 (4%) and postoperative complications in 26 (6%). In multivariable regression, nerve sparing, and template resection improved ejaculatory function significantly (template vs bilateral resection [odds ratio (OR) 19.4, 95% confidence interval (CI) 6.5-75.6], nerve sparing vs non-nerve sparing [OR 5.9, 95% CI 2.3-16.1]). In 91 men treated with primary RPLND, nerve sparing and template resection, normal postoperative ejaculation was reported in 96%. During a median follow-up of 33 months, relapse was detected in 39 (9%) of which one with port site (< 1%), one with peritoneal recurrence and 10 (2%) with retroperitoneum recurrences.
conclusionThe low proportion of complications or peritoneal recurrences and high proportion of men with normal postoperative ejaculatory function supports further miRPLND studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.